Ractigen Therapeutics is an early-stage biotech company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.
Location: China, Jiangsu, Suzhou City
Employees: 51-200
Total raised: $30M
Founded date: 2017
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.01.2022 | Series A | $30M | SDIC Ventu... |
Mentions in press and media 15
| Date | Title | Description |
| 12.09.2024 | Ractigen's RAG-17: A Beacon of Hope in ALS Treatment | In the world of medicine, breakthroughs often emerge from the shadows of despair. Ractigen Therapeutics is shining a light on amyotrophic lateral sclerosis (ALS) with its latest development, RAG-17. This small interfering RNA (siRNA) therap... |
| 10.09.2024 | Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial | NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initi... |
| 10.09.2024 | Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial | NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initi... |
| 22.08.2024 | Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy | NANTONG and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug De... |
| 31.07.2024 | Ractigen's RAG-18: A Beacon of Hope for Duchenne Muscular Dystrophy | In the world of rare diseases, hope often flickers like a candle in the dark. Recently, Ractigen Therapeutics ignited that flame with its announcement regarding RAG-18, a groundbreaking treatment for Duchenne Muscular Dystrophy (DMD). The U... |
| 25.07.2024 | Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy | SUZHOU, China, July 25, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Des... |
| 25.07.2024 | Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy | SUZHOU, China, July 25, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Des... |
| 21.05.2024 | Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy | SUZHOU, China, May 21, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been granted Fast Track Designation (FTD) by th... |
| 21.05.2024 | Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy | SUZHOU, China, May 21, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been granted Fast Track Designation (FTD) by th... |
| 15.05.2024 | Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients | SUZHOU, China, May 15, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing pioneering therapies, today announces that the Center for Drug Evaluation (CDE) of China's National Medical P... |
Show more